Vitamin E or Silymarin for Fatty Liver Disease in Adults Without Diabetes
Compares vitamin E, silymarin and placebo in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Vitamin E Versus Silymarin in Non Diabetic MASLD Patients
Key facts
- Where
- Tanta, EgyptSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07863648, who can take part
Where in Egypt
- Faculty of MedicineTanta, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kafrelsheikh University
- Trial code
- NCT07863648
- Record updated
- 13 October 2026
- Original description
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), is a chronic liver condition marked by excessive fat buildup (steatosis) in liver cells, linked to at least one metabolic risk factor like obesity, type 2 diabetes, high blood lipids, or hypertension. Vitamin E serves as a recommended antioxidant therapy for select MASLD patients. It reduces liver inflammation markers such as ALT and AST, alongside benefits in steatosis and MASH resolution. Silymarin has clinical evidence supports its use as an adjunctive hepatoprotective agent due to antioxidant, anti-inflammatory, and antifibrotic effects.Read full original descriptionShow less
A Randomized Controlled Evaluation of Vitamin E Versus Silymarin on Liver Through Modulation of mRNA Profiles, NLRP3 Inflammasome Signaling, and Oxidative Stress in Non Diabetic MASLD Patients
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), is a chronic liver condition marked by excessive fat buildup (steatosis) in liver cells, linked to at least one metabolic risk factor like obesity, type 2 diabetes, high blood lipids, or hypertension. Vitamin E serves as a recommended antioxidant therapy for select MASLD patients. It reduces liver inflammation markers such as ALT and AST, alongside benefits in steatosis and MASH resolution. Silymarin has clinical evidence supports its use as an adjunctive hepatoprotective agent due to antioxidant, anti-inflammatory, and antifibrotic effects.
Inclusion: Adults (18-65 y),; Diagnosed with MASLD (CAP ≥248 dB/m on FibroScan, ALT >40 IU/L),; Non-diabetic (HbA1c <6.5%, fasting glucose <126 mg/dL),; BMI 25-40 kg/m²,; No alcohol (>20 g/d women, >30 g/d men).
Exclusion: Decompensated liver disease,; Other liver diseases, decompensated cirrhosis,; Cirrhosis (LSM >12 kPa),; Pregnancy, or; use of vitamin E/silymarin within 3 months.